Dokumentanzeige 

Zur Kurzanzeige

Título
Transcriptomics reveals new regulatory mechanisms involved in benralizumab response
dc.contributor.authorEstravís Sastre, Miguel 
dc.contributor.authorPérez Pazos, Jacqueline
dc.contributor.authorMoreno‐Jimenez, Emma
dc.contributor.authorTriviño, Juan Carlos
dc.contributor.authorGarcía Sánchez, María Asunción 
dc.contributor.authorGómez‐García, Manuel
dc.contributor.authorMorgado, Natalia
dc.contributor.authorRamos González, Jacinto 
dc.contributor.authorGil Melcón, María
dc.contributor.authorMartín García, Cristina
dc.contributor.authorMuñoz Bellido, Francisco Javier 
dc.contributor.authorSanz Lozano, Catalina Sofía 
dc.contributor.authorIsidoro García, María 
dc.contributor.authorDávila González, Ignacio Jesús 
dc.date.accessioned2024-07-03T11:30:35Z
dc.date.available2024-07-03T11:30:35Z
dc.date.issued2023-11
dc.identifier.citationEstravís M, Pérez-Pazos J, Moreno-Jimenez E, Triviño JC, García-Sánchez A, Gómez-García M, Morgado N, Ramos-González J, Gil-Melcón M, Martín-García C, Muñoz-Bellido F, Sanz C, Isidoro-García M, Dávila I. Transcriptomics reveals new regulatory mechanisms involved in benralizumab response. Allergy. 2023 Nov;78(11):3023-3026. doi: 10.1111/all.15869. Epub 2023 Aug 28. PMID: 37641395.es_ES
dc.identifier.issn0105-4538
dc.identifier.urihttp://hdl.handle.net/10366/158780
dc.description.abstract[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge. In this prospective observational study, we analyzed transcriptomic changes in peripheral whole blood samples from 15 severe asthmatic patients treated with benralizumab for 6 months. The study included patients with two frequent comorbidities: nasal polyposis (CRSwNP) and NSAID-exacerbated respiratory disease (N-ERD)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII); European Union -NextGeneration EU; Junta de Castilla y Leónes_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBenralizumabes_ES
dc.subjectTranscriptomicses_ES
dc.subjectAsthma biomarkerses_ES
dc.subjectCRSwNPes_ES
dc.subjectN-ERDes_ES
dc.subjectExacerbated respiratory diseasees_ES
dc.subject.meshGenetics *
dc.subject.meshAllergy and Immunology *
dc.titleTranscriptomics reveals new regulatory mechanisms involved in benralizumab responsees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1111/all.15869es_ES
dc.subject.unesco3207.01 Alergiases_ES
dc.subject.unesco2409 Genéticaes_ES
dc.identifier.doi10.1111/all.15869
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid37641395
dc.identifier.essn1398-9995
dc.journal.titleAllergyes_ES
dc.volume.number78es_ES
dc.issue.number11es_ES
dc.page.initial3023es_ES
dc.page.final3026es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsalergia e inmunología *
dc.subject.decsgenética *


Dateien zu dieser Ressource

Thumbnail
Name:
2023_DMG_EstravisM_Allergy_Let ...
Größe:
1.880Mb
Format:
PDF
Beschreibung:
Artículo principal
Öffnen

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional